ME 108

Drug Profile

ME 108

Alternative Names: Allergy vaccine - Pharmexa; Anti-IgE allergy vaccine - Pharmexa; AutoVac IgE vaccine - Pharmexa

Latest Information Update: 21 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmexa
  • Class Allergens; Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypersensitivity

Most Recent Events

  • 22 Jun 2001 M&E Biotech is now called Pharmexa
  • 27 Nov 1998 Preclinical development for Allergy in Denmark (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top